Navigation Links
Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Date:6/26/2008

(BCVA) of 15 letters or greater from baseline. In addition, both the low dose and the high dose of Iluvien resulted in a significant reduction in retinal thickness as compared to the baseline.

From a safety perspective, no adverse events related to intraocular, or inner eye, pressure were seen in the low dose patients, while 12 percent of the high dose patients experienced intraocular pressure increases of greater than 30 mmHg. Additionally, the only adverse event related to cataract formation was reported in a patient in the high dose group.

The early readout from this PK Study provides further insight into the dose-response of FA in the treatment of DME. By comparison, Bausch & Lomb's Retisert(R) (fluocinolone acetonide intravitreal implant), with an initial release dose of 0.6 microgram per day, was also studied in a DME population. It demonstrated a significant improvement in visual acuity at one year, comparable to the Iluvien results reported here; however, a lower dose was not tested. Therefore, it has not been determined if Retisert's dosage level represents the lowest efficacious dose for DME.

"We believe this early readout from our PK Study supports our premise that lower doses of FA delivered by Iluvien will provide visual acuity improvements while reducing the risk of ocular side effects commonly associated with the use of corticosteroids," said Ken Green, Ph.D., chief scientific officer for Alimera.

Data from this open-label study will be evaluated on an ongoing basis with interim looks at months 3, 6, 12, 18, 24, 30 and 36. Except for the month 12 and final month 36 looks, when the database will be fully locked, interim evaluations will be based on unaudited data. The last patient was enrolled in this study at the end of February 2007.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharma
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:9/1/2015)... ... September 01, 2015 , ... According to a ... with type 2 diabetes that participated in a three year study about weight loss ... the line if they elected weight loss surgery at the onset of the trial. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... its annual Light it Red for Lymphoma awareness initiative, the nation’s premier and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty Gives Back Art ... Behind the Fashion” on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, ... the collaboration between fashion and professional hair, makeup and nail design. , The ...
(Date:9/1/2015)... Seattle, WA (PRWEB) , ... September 01, 2015 , ... ... despite increasing awareness of societal issues and needs. Money for Good 2015, released today ... for solving it. There’s an annual potential to mobilize up to $22B in new ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State ... universities across the country in stemming sexual assaults on their campuses. , The ... a consortium of sexual assault researchers and student affairs professionals responding to calls ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2
... , Nurtur Receives Accreditation for Five Population Health ... Health Impact Institute (PHII), a non-profit 501(c)(3) organization, is pleased ... Healthcare Transparency Accreditation Program, v 1.0 (H-TAP(TM)) after two years ... based in Farmington, CT is the first organization to receive ...
... studies suggest that adding flaxseed oil to the diet could ... with diabetes, according to a report to be published in ... Health . Mer Harvi and colleagues at the National ... diabetes on bone health and evaluated how flaxseed oil in ...
... die than whites, study finds , MONDAY, Nov. 23 ... don,t explain why black colon cancer patients have lower ... an effort to determine why blacks have lower survival ... cancers, investigators have explored a variety factors, such as ...
... Calif., Nov. 23 , Dear Isis Supporters and Shareholders, , ... support of Isis. We believe we are at one of ... at the end of the beginning of creating a unique company ... of the issues haunting the pharmaceutical industry. , Our ...
... ... Best New Technology Provider for its QlikView Business Intelligence Software , ... Radnor, PA (PRWEB) ... today announced that it was recognized with the Healthcare IT Innovation™ Award in ...
... , NEW YORK, Nov. 23 With ... few extra inches and pounds. Lady Foot Locker recommends ... do the work. With the right footwear, it can do exactly ... Reebok,s EasyTone and Skechers, Shape Ups , can ...
Cached Medicine News:Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Flaxseed oil and osteoporosis 2Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2Health News:Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders 2Health News:QlikTech Wins Healthcare IT Innovation™ Award 2Health News:QlikTech Wins Healthcare IT Innovation™ Award 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 4Health News:Make the Most of Your Holiday Haul with Lady Foot Locker 2
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: